IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (AMEX:COR) received the formal letter from the U.S. Food and Drug Administration on Monday, October 23, 2006 regarding the lifting of the clinical hold on Cortex’s lead product candidate, AMPAKINE® CX717. The Company will host a conference call at 4:00 p.m. ET (1:00 p.m. PT) on Thursday, October 26th to review the steps it is taking to advance the development of CX717.
